Feed - Buzzberg

20:30
Jul 30 ◎

SYK FY2026 Q2 Watch

Stryker Corporation (SYK) FY2026 Q2 Earnings Call

SYK ▾

Kevin Lobo

Management raised the lower end of full-year organic sales guidance to 8.3-9.3%, signaling strong demand and production ramp recovery.

"We feel very, very confident. Otherwise, we wouldn't have raised the lower end of our sales guidance."

SYK WATCH

HIGH

20:30
Apr 30 ◎

SYK FY2026 Q1 Watch

Stryker Corporation (SYK) FY2026 Q1 Earnings Call

21:30
Jan 29 ◎

SYK FY2025 Q4 Watch

Stryker Corporation (SYK) FY2025 Q4 Earnings Call

ZBH SNN BSX PEN SYK ▾

Jason Beach

Stryker's record Mako 4 installation quarter and elevated capital order book into 2026 point to continued hospital spending on orthopaedic robotics, putting share pressure on implant rivals with less robot scale. — Another record placement wave plus high Mako utilization implies Stryker's robotic attach continues to take knee/hip share from competitors that lack comparable installed-base momentum.

"Our capital order book continues to be elevated as we enter 2026. Next, powered by Mako 4, we delivered a stunning quarter and year of Mako installations with yet another record quarter, both in the US and worldwide."

ZBH WATCH SNN WATCH

Jason Beach

Inari peripheral vascular destocking was heavier than expected in Q4 but is minimal by Q1; high-teens procedural growth shows strong underlying PE thrombectomy demand, a positive read-across to competing players. — If destocking clears by Q1, Stryker's peripheral vascular business re-accelerates, intensifying competition in the pulmonary embolism/thrombectomy market.

"Inari, which is now known as our peripheral vascular business, had a strong finish to the year, highlighted by robust procedural growth in the high teens that was partially offset by the stocking, which will be minimal in Q1."

BSX WATCH

Jason Beach

Stryker acknowledged its ischemic neurovascular business has been pressured for two years, with a new large-bore aspiration catheter only in early US launch, while hemorrhagic has overtaken market leadership — a mixed competitive signal for neurovascular rivals. — Competitors in ischemic stroke aspiration still have a window before Stryker's Broadway launch scales globally, while Stryker's hemorrhagic strength raises the bar in that segment.

PEN WATCH

Kevin Lobo

Management guided FY2026 to 8-9.5% organic growth and EPS of $14.90-$15.10, citing record Mako installations, an elevated capital order book, and continued margin expansion despite higher tariffs.

"We have momentum entering 2026 and expect to continue delivering growth at the high end of MedTech, which is reflected in our full year 2026 guidance."

SYK WATCH

HIGH

Feed — Buzzberg